期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心力衰竭新型药物治疗现状 被引量：9

Current status of new drug therapy in heart failure
原文传递
导出
摘要 心力衰竭是一组复杂临床综合征。在心力衰竭的治疗中,药物治疗一直占有重要地位,近年来新研发的药物取得循证证据,为临床进一步改善心力衰竭患者预后提供新的方法。本文按慢性和急性心力衰竭的分类方法对其药物治疗进行综述。 Heart failure is a complex clinical syndrome.Drugs act an important role in the anti-heart failure treatment.Recent years,new explored drugs have got clinical evidence,which provide new approach to improve patients＇ prognosis.This article reviews the drug therapy according to the classification of chronic heart failure and acute heart failure.
作者 贾琼 李强 徐兆龙
机构地区 辽宁医学院附属第一医院心内科
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2016年第7期745-748,共4页 Journal of Clinical Cardiology
基金 辽宁省科学技术计划项目(No:2012225019)
关键词 心力衰竭 药物治疗 进展 heart failure drug therapy progress
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献24

  • 1中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量：4680
  • 2戴闺柱.心力衰竭的今天 我们在哪里？[J].中华心血管病杂志,2013,41(8):638-641. 被引量：3
  • 3SWEDBERG K,KOMAJDA M,BOHM M,et al.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376:875-885.
  • 4VITOVEC J,SPINAROVA L,SPINAR J.Effects of selective heart rate reduction with Ivabradine on left ventricular remodeling and health related quality of life:result frome the SHIFT sub-studies[J].Vnitr Lek,2012,58:612-617.
  • 5VAN ESCH J H,MOLTZER E,VAN VEGHEL R,et al.Beneficial cardiac effects of the rennin inhibitors aliskiren in spontaneously hypertensive rats[J].Hypertens,2010,28:2145-2155.
  • 6MCMURRAY J J,PACKER M,DESAI A S,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371:993-1004.
  • 7MOE G W,EZEKOWITZ J A,O'MEARA E,et al.The 2014Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update:anemia,biomarkers,and recent therapeutic trial implications[J].Can J Cardiol,2015,31:3-16.
  • 8PITT B,ZANNAD F,REMME W J,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators[J].N Engl JMed,1999,341:709-717.
  • 9ROSSIGNOL P,DOBRE D,MCMURRAY J J,et al.Incidence,determinants,and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy:results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure(EMPHASIS-HF)[J].Circ Heart Fail,2014,7:51-58.
  • 10PITT B,REMME W,ZANNAD F,et al.Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction[J].N Engl J Med,2003,348:1309-1321.

二级参考文献28

  • 1Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eng J Med,1984,311:819-823.
  • 2Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines [ J/OL 1 [ published online ahead of print June 5. 2013 ]. Circulation, 2013 E 2013-06-21 ~ http://circ, ahajournals, org/content/early/2013/06/03/ CIR. ObO 13 e31829e8776, long.
  • 3Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/ ATTS/PCNA/SCAI/STS guideIine for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundatiotr/American Heart Association task force on practiee guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular AngiogTaphy and Interventions, and Society of Thoracic Surgeons. Circulation, 2012,126:3097-3137.
  • 4O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction : executive summary : a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines . Circulation, 2013, 127:529-555.
  • 5McMurry JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 :the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association ( HFA ) of the ESC. Eur Heart J,2012, 33 : 1787-1847.
  • 6Bristow MR, Saxon LA, Boehmer J, et al. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med, 2004,350:2140-2150.
  • 7Clinical outcome with enalapril in symptomatic chronic heart failure : a dose comparison. Eur Heart J, 1998,19:481-489.
  • 8Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation, 1999,100: 2312-2318.
  • 9Hunt SA, Abraham WT, Chin MH, et al, ACC/AHA 2005 guideline update for the diagnosis and umnagement of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure ) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005,112: e154-e235.
  • 10Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, 2009, 374: 1840-1848.

共引文献4680

同被引文献72

引证文献9

二级引证文献61

临床心血管病杂志
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部